Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicaemia and pneumonia.
59 patients with suspected or verified septicaemia and 87 patients with suspected or verified bacterial pneumonia were treated with either antibiotics alone or antibiotics combined with a pepsin-treated human gamma globulin (Gamma-Venin). The gamma globulin was given intravenously in repeated doses of 0.15 g/kg body weight. Extensive clinical and laboratory investigations were performed repeatedly in a strictly standardized fashion. Neither the septicaemia group nor the pneumonia group presented significant differences between treated patients and controls for any of the clinical and laboratory variables studied. Hospital stay, duration of fever and symptoms were also unaffected by the gamma globulin treatment. Subdivision of the material according to aetiology provided no additional information. In 9 patients adverse reactions were seen, e.g., shock in 2 individuals.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010434:Pepsin A; D011014:Pneumonia / Q000188:drug therapy / Q000628:therapy*; D011446:Prospective Studies; D011897:Random Allocation; D018805:Sepsis / Q000188:drug therapy / Q000628:therapy*; D005719:gamma-Globulins / Q000009:adverse effects / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D005719:gamma-Globulins; D010434:Pepsin A